Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $202.67 billion. The enterprise value is $230.52 billion.
| Market Cap | 202.67B |
| Enterprise Value | 230.52B |
Important Dates
The next estimated earnings date is Thursday, October 30, 2025, before market open.
| Earnings Date | Oct 30, 2025 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
Merck & Co. has 2.50 billion shares outstanding. The number of shares has decreased by -0.77% in one year.
| Current Share Class | 2.50B |
| Shares Outstanding | 2.50B |
| Shares Change (YoY) | -0.77% |
| Shares Change (QoQ) | -0.71% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 79.90% |
| Float | 2.49B |
Valuation Ratios
The trailing PE ratio is 12.51 and the forward PE ratio is 8.86. Merck & Co.'s PEG ratio is 0.94.
| PE Ratio | 12.51 |
| Forward PE | 8.86 |
| PS Ratio | 3.22 |
| Forward PS | 3.07 |
| PB Ratio | 4.14 |
| P/TBV Ratio | 16.69 |
| P/FCF Ratio | 13.84 |
| P/OCF Ratio | 10.99 |
| PEG Ratio | 0.94 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.14, with an EV/FCF ratio of 15.66.
| EV / Earnings | 14.05 |
| EV / Sales | 3.62 |
| EV / EBITDA | 8.14 |
| EV / EBIT | 9.63 |
| EV / FCF | 15.66 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.42 |
| Quick Ratio | 0.82 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.23 |
| Debt / FCF | 2.40 |
| Interest Coverage | 18.77 |
Financial Efficiency
Return on equity (ROE) is 35.42% and return on invested capital (ROIC) is 18.04%.
| Return on Equity (ROE) | 35.42% |
| Return on Assets (ROA) | 13.01% |
| Return on Invested Capital (ROIC) | 18.04% |
| Return on Capital Employed (ROCE) | 26.18% |
| Revenue Per Employee | $848,213 |
| Profits Per Employee | $218,747 |
| Employee Count | 75,000 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 2.20 |
Taxes
In the past 12 months, Merck & Co. has paid $2.74 billion in taxes.
| Income Tax | 2.74B |
| Effective Tax Rate | 14.32% |
Stock Price Statistics
The stock price has decreased by -31.21% in the last 52 weeks. The beta is 0.38, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -31.21% |
| 50-Day Moving Average | 82.85 |
| 200-Day Moving Average | 86.98 |
| Relative Strength Index (RSI) | 41.35 |
| Average Volume (20 Days) | 11,611,285 |
Short Selling Information
The latest short interest is 23.83 million, so 0.95% of the outstanding shares have been sold short.
| Short Interest | 23.83M |
| Short Previous Month | 25.88M |
| Short % of Shares Out | 0.95% |
| Short % of Float | 0.96% |
| Short Ratio (days to cover) | 1.96 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $63.62 billion and earned $16.41 billion in profits. Earnings per share was $6.49.
| Revenue | 63.62B |
| Gross Profit | 49.25B |
| Operating Income | 23.95B |
| Pretax Income | n/a |
| Net Income | 16.41B |
| EBITDA | 28.33B |
| EBIT | 23.95B |
| Earnings Per Share (EPS) | $6.49 |
Balance Sheet
The company has $8.62 billion in cash and $35.40 billion in debt, giving a net cash position of -$26.78 billion or -$10.72 per share.
| Cash & Cash Equivalents | 8.62B |
| Total Debt | 35.40B |
| Net Cash | -26.78B |
| Net Cash Per Share | -$10.72 |
| Equity (Book Value) | 49.06B |
| Book Value Per Share | 19.57 |
| Working Capital | 11.03B |
Cash Flow
In the last 12 months, operating cash flow was $18.53 billion and capital expenditures -$3.81 billion, giving a free cash flow of $14.72 billion.
| Operating Cash Flow | 18.53B |
| Capital Expenditures | -3.81B |
| Free Cash Flow | 14.72B |
| FCF Per Share | $5.89 |
Margins
Gross margin is 77.41%, with operating and profit margins of 37.64% and 25.79%.
| Gross Margin | 77.41% |
| Operating Margin | 37.64% |
| Pretax Margin | 30.12% |
| Profit Margin | 25.79% |
| EBITDA Margin | 44.53% |
| EBIT Margin | 37.64% |
| FCF Margin | 23.14% |
Dividends & Yields
This stock pays an annual dividend of $3.24, which amounts to a dividend yield of 3.99%.
| Dividend Per Share | $3.24 |
| Dividend Yield | 3.99% |
| Dividend Growth (YoY) | 5.19% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 49.96% |
| Buyback Yield | 0.77% |
| Shareholder Yield | 4.73% |
| Earnings Yield | 8.05% |
| FCF Yield | 7.23% |
Analyst Forecast
The average price target for Merck & Co. is $107.21, which is 32.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $107.21 |
| Price Target Difference | 32.13% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 2.01% |
| EPS Growth Forecast (5Y) | 8.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 4.33 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.33 |
| Piotroski F-Score | 6 |